POST Online Media Lite Edition


Pfizer/Allergan: Brent Saunders president, COO of the combined company

Staff writer |
New York, N.Y., USA - February 10, 2016, New York, N.Y., USA - Pfizer Inc. announced the executive leadership team for the combined Pfizer and Allergan plc business following the close of the proposed transaction.

Article continues below

Following the closing, Brent Saunders will become President and Chief Operating Officer of the combined company with responsibility for the oversight of Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions.

Mr. Saunders previously served as Chief Executive Officer and President of Forest Laboratories and had served as a Director of Forest since 2011. Mr. Saunders has significant healthcare industry expertise and a proven track-record leading business transformations and integrations.

Prior to Forest, he was chief executive officer of Bausch + Lomb, a leading global eye health company, serving in this capacity from March 2010 until August 2013.

Mr. Saunders also held a number of leadership positions at Schering-Plough, including the position of president of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences.

Before joining Schering-Plough, Mr. Saunders was a partner and head of Compliance Business Advisory at PricewaterhouseCoopers LLP.

Prior to that, he was chief risk officer at Coventry Health Care and senior vice president, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as chief compliance officer for the Thomas Jefferson University Health System.

Mr. Saunders serves on the Board of Trustees of the University of Pittsburgh. He is also the former Chairman of the New York chapter of the American Heart Association. He is a member of the Business Council and PhRMA.

He earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his bachelor’s degree from the University of Pittsburgh.

Effective immediately and through the closing of the transaction Pfizer’s Global Innovative Pharma (GIP) business and its Vaccines, Oncology and Consumer (VOC) business will operate separately under the leadership of Albert Bourla, currently Group President, VOC.

Upon the closing of the transaction, the Vaccines and Oncology businesses will be combined with the GIP business, and Albert Bourla will become Group President, Global Innovative Pharma, leading all of these businesses.

In addition, following the close of the transaction, the combined company will create a new operating segment named Global Specialty and Consumer Brands that will include Pfizer’s Consumer Healthcare unit and Allergan’s ophthalmology and aesthetics businesses, and Botox Therapeutic and Cosmetic.

Bill Meury, currently Executive Vice President and President Branded Pharma at Allergan, will become Group President, Global Specialty and Consumer Brands, Pfizer.

After the close of the proposed transaction, Pfizer will continue to manage the combined company’s commercial operations through two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business will be composed of two operating segments: the Global Innovative Pharmaceutical and the Global Specialty and Consumer Brands segment.

The Established Products business will continue to be led by John Young, and consist of the Global Established Pharmaceutical segment, including all legacy Hospira commercial operations.

Upon the close of the transaction, the following executives will be members of the company’s executive leadership team, reporting to Brent Saunders:

Albert Bourla, Group President, Global Innovative Pharma

Tony Maddaluna, Executive Vice President, President Pfizer Global Supply

Bill Meury, Group President, Global Specialty and Consumer Brands

Laurie Olson, Executive Vice President, Strategy, Portfolio and Commercial Operations

John Young, Group President, Global Established Pharma

The following Pfizer executives are continuing in their roles reporting to Ian Read, Pfizer Chairman and Chief Executive Officer:

Frank D’Amelio – Executive Vice President, Business Operations and Chief Financial Officer

Mikael Dolsten – President, Worldwide Research and Development

Chuck Hill – Executive Vice President, Worldwide Human Resources

Rady Johnson – Executive Vice President, Chief Compliance and Risk Officer

Doug Lankler – Executive Vice President, General Counsel

Freda Lewis-Hall – Executive Vice President, Chief Medical Officer

Sally Susman – Executive Vice President, Corporate Affairs